ALL
Pharma in China
Pharma Experts
Market News
Products Guide
Brand Story
-
Lilly enlists patients to raise cluster headache awareness after Emgality scores second nod
June 28, 2019Cluster headache pain is so intense, one patient describes banging his head against the refrigerator door to make it stop. -
FDA ‘yes’ for Emgality in cluster headache
June 05, 2019The US Food and Drug Administration (FDA) has announced the approval of the first treatment for episodic cluster headache that reduces the frequency of attacks, Eli Lilly’s Emgality (galcanezumab-gnlm). -
Lilly submits New Drug Application to the FDA for lasmiditan for acute treatment of migraine, receives Breakthrough Therapy Designation for Emgality™ (galcanezumab-gnlm) for prevention of episodic cluster headache
November 17, 2018The NDA for lasmiditan includes data from two Phase 3 single-attack studies (SAMURAI and SPARTAN), which evaluated the safety and efficacy of lasmiditan for the acute treatment of migraine.
Pharma Sources Insight January 2025
